Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

Mezquita, Laura; Auclin, Édouard; Ferrara, Roberto; Charrier, Mélinda; Remón, Jordi; Planchard, David; Ponce, Santiago; Ares, Luis Paz; Leroy, Laura; Audigier-Valette, Clarisse; Felip, Enriqueta; Zerón-Medina, Jorge; Garrido, Pilar; Brosseau, Solenn; Zalcman, Gérard; Mazières, Julien; Caramela, Caroline; Lahmar, J.; Adam, Julien; Chaput, Nathalie; Soria, Jean Charles; Besse, Benjamin

doi:10.1001/jamaoncol.2017.4771

Cited by 672 publications

(803 citation statements)

References 34 publications

Supporting

Mentioning

761

Contrasting

Unclassified

Order By: Relevance

“…A recent study demonstrated that high NLR and LDH correlated with poor outcomes after ICB treatment in lung cancer . It has also been reported that the efficacy of ICB treatment depends on suitable immune phenotypes .…”

Section: Resultsmentioning

confidence: 98%

See 1 more Smart Citation

Characteristics and prognostic significance of profiling the peripheral blood T‐cell receptor repertoire in patients with advanced lung cancer

Liu

Yang

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Lung cancer is one of the greatest threats to human health, and is initially detected and attacked by the immune system through tumor‐reactive T cells. The aim of this study was to determine the basic characteristics and clinical significance of the peripheral blood T‐cell receptor (TCR) repertoire in patients with advanced lung cancer. To comprehensively profile the TCR repertoire, high‐throughput sequencing was used to identify hypervariable rearrangements of complementarity determining region 3 (CDR3) of the TCR β chain in peripheral blood samples from 64 advanced lung cancer patients and 31 healthy controls. We found that the TCR repertoire differed substantially between lung cancer patients and healthy controls in terms of CDR3 clonotype, diversity, V/J segment usage, and sequence. Specifically, baseline diversity correlated with several clinical characteristics, and high diversity reflected a better immune status. Dynamic detection of the TCR repertoire during anticancer treatment was useful for prognosis. Both increased diversity and high overlap rate between the pre‐ and post‐treatment TCR repertoires indicated clinical benefit. Combination of the diversity and overlap rate was used to categorize patients into immune improved or immune worsened groups and demonstrated enhanced prognostic significance. In conclusion, TCR repertoire analysis served as a useful indicator of disease development and prognosis in advanced lung cancer and may be utilized to direct future immunotherapy.

show abstract

Section: Resultsmentioning

confidence: 98%

“…). After categorizing patients using previously described cut‐off values for NLR and LDH, we found that both high NLR and LDH groups exhibited lower clonotype and diversity (Supporting Information Fig. S7).…”

Section: Resultsmentioning

confidence: 99%

Characteristics and prognostic significance of profiling the peripheral blood T‐cell receptor repertoire in patients with advanced lung cancer

Liu

Yang

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Although many biomarkers for ICI treatment have been previously verified, most cannot be used in the real‐world clinical setting because they require specialized equipment or are too expensive to analyze. A recent study explored prognostic indexes based on pretreatment derived neutrophil‐to‐lymphocyte ratios and lactate dehydrogenase in patients with advanced NSCLC treated with ICIs …”

Section: Discussionmentioning

confidence: 99%

Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors

et al. 2019

View full text Add to dashboard Cite

Background The use of baseline tumor burden (TB) as a prognostic factor for non‐small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) and associations between TB and other prognostic biomarkers remain unclear. In this study, we investigated the association between TB and survival in NSCLC patients treated with ICIs in comparison with other biomarkers. Methods We retrospectively evaluated 83 NSCLC patients with ICIs administered between February 2016 and December 2018. TB was measured as the sum of the unidimensional diameters of up to five target lesions. Results The median observation period was 14.2 months. A total of 42 patients died during the follow‐up. Univariate Cox regression analysis showed that baseline TB was associated with OS. Cox regression analysis adjusted for Eastern Cooperative Oncology Group performance status (ECOG PS) alone or with addition of programmed cell death ligand 1 expression and treatment line showed that TB was a prognostic factor for OS. Using time‐dependent receiver operating characteristic curve analysis, the optimal TB cutoff for predicting OS was 12 cm, and patients were divided into a high TB group (n = 21) and a low TB group (n = 62). The low TB group achieved significantly longer OS than the high TB group (median OS: 18.5 months, [95% CI = 11.7‐not reached] vs. 2.3 months [95% CI = 1.3–2.9], P < 0.001). Conclusion TB is a useful, clinically measurable prognostic factor of survival in NSCLC patients treated with ICIs.

show abstract

“…The dynamics of NLR and ANC during nivolumab treatment may be associated with the efficacy of the subsequent salvage chemotherapy. Many studies have shown that low baseline NLR and ANC predict the efficacy of nivolumab therapy in various cancers . More recent studies have shown that an early decrease in NLR during treatment with PD‐1 inhibitors predicts its efficacy .…”

Section: Discussionmentioning

confidence: 99%

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study

et al. 2018

View full text Add to dashboard Cite

Several recent studies have shown that salvage chemotherapy following PD‐1 blockade produces high antitumor activity in some patients with non‐small lung cancer (NSCLC). However, the underlying synergistic mechanisms remain uncertain. The blood neutrophil‐to‐lymphocyte ratio (NLR) and absolute neutrophil count (ANC) can reflect the number of circulating myeloid‐derived suppressor cells and tumor‐associated neutrophils. The immunosuppressive status of the tumor microenvironment could be monitored by the time‐series patterns of NLR and ANC. The dynamics of NLR and ANC during nivolumab treatment were retrospectively explored in 15 patients: 8 patients receiving subsequent salvage chemotherapy (2 groups: 3 non‐responders and 5 responders), and 7 responders to nivolumab alone (2 groups: 4 partial response and 3 complete response). The dynamics of NLR and ANC during nivolumab differed among these four groups (NLR P = 0.045, ANC P = 0.067). NLR and ANC during nivolumab treatment increased over time in non‐responders to salvage chemotherapy, with an inverse relationship between drug response and NLR or ANC at four to six weeks among the four groups. We hypothesize that the early dynamics of NLR and ANC during nivolumab may be associated with the late efficacy of subsequent salvage chemotherapy. Further studies involving a large cohort are needed to confirm these findings, which could provide insight into the role of myeloid immunosuppressor cells in combination PD‐1 blockade and chemotherapy.

show abstract

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

Cited by 672 publications

References 34 publications

Characteristics and prognostic significance of profiling the peripheral blood T‐cell receptor repertoire in patients with advanced lung cancer

Characteristics and prognostic significance of profiling the peripheral blood T‐cell receptor repertoire in patients with advanced lung cancer

Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study

Contact Info

Product

Resources

About